Eric Topol April 29, 2024
Counterbalanced by some disappointments
Our gold standard of assessing efficacy in medicine is a large-scale randomized trial. Last week we reviewed all 88 published randomized medical A.I. trials. Most were targeting intermediate endpoints, such as detection of a colon polyp or an abnormal mammogram. None were focused on reducing mortality as the primary endpoint.
Today that changed. In a paper published at Nature Medicine, nearly 16,000 patients at 2 hospitals in Taiwan were randomly assigned to their physician getting an AI alert of their patient’s electrocardiogram compared to conventional care (single-blind design), with the primary endpoint of all-cause mortality at 90 days.
The main results are summarized below. For the overall trial there was a statistically significant 17% reduction of...
Today's Sponsors
Today's Sponsor